Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

NCT02097641 is registered in ClinicalTrials.gov with Michael A. Matthay as lead sponsor.

NCT NCT02097641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02097641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
Lead sponsor
Michael A. Matthay
Phase
Phase 2
Overall status
Completed
Start date
March 15, 2014
Completion date
February 9, 2018
Enrollment
60 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory distress syndrome, adult